Running digitally for 2021, the 2nd TCR-based Therapies Summit is the leading industry-focused meeting dedicated to supercharging the expanded TCR repertoire through enhanced target specificity, density and binding affinity for solid tumor indications.
This June (8-10), join this exclusive community online to virtually network and learn from the leading experts in pharma, biotech and academia, as we discuss how to how to overcome on-target off-tumor toxicity, enhance the binding affinity and avidity of TCR-T therapies and utilize dual targeting and combination approaches for enhanced efficacy.
Navigate across 3 days packed with dedicated, interactive formats exploring the identification of novel targets, the importance of safety profiling, and discuss optimization of soluble approaches for the development of next-generation TCR-T products.
Time: 09:30 to 16:15
Conference Only: USD 2499.00,
Conference + 2 Workshops: USD 3297.00,
Conference + Focus Day: USD 3297.00
Speakers: Hans-Peter Gerber SVP and CSO 3T Biosciences, Joseph Dukes VP Translational Sciences Enara Bio, Leah Sibener Co-founder, Head of Therapeutic Discovery 3T Bioscience, Noah Pefaur Principle Scientist Abbvie, Reagan Jarvis CEO Anocca, Reno Debets Professor, Laboratory of Tumor Immunology, Department of Medical Oncology, Chief Scientific Officer Erasmus MC Cancer Institute, Pan Cancer T B.V., Ali Mohamed VP, CMC Immatics, Cheng Liu Founder and CEO Eureka Therapeutics, David Scheinberg Chairman, Molecular Pharmacology Program; and Experimental Therapeutics Center Memorial Sloan Kettering Cancer Center, Dolores Schendel CEO and CSO Medigene AG, Mohammed Dar CMO Immunocore, Natalia Venetz Scientist Oncology Research Molecular Partners AG, David Southwell President, CEO TScan Therapeutics, Erika Von Euw Director, Translational Research T-Cure Biosciences Inc, Gang Zeng CEO T-Cure Biosciences Inc, Marcus Butler Medical Oncologist, Tumor Immunotherapy Program Princess Margaret Cancer Centre, Paul Lammers President and CEO Triumvira Immunologics, Shannon Oda Assistant Professor Seattle Children's Research Institute and University of Washington, Namir Hassan CEO Zelluna Immunotherapy, Raffaele Baffa CMO Ziopharm Oncology